All reports
All KCE reports are available in Dutch, French and English under several formats. Form and language of the reports
- 2005 (4) Apply 2005 filter
- 2007 (3) Apply 2007 filter
- 2008 (2) Apply 2008 filter
- 2009 (1) Apply 2009 filter
- 2010 (5) Apply 2010 filter
- 2011 (2) Apply 2011 filter
- 2012 (2) Apply 2012 filter
- 2013 (2) Apply 2013 filter
- 2014 (1) Apply 2014 filter
- 2015 (2) Apply 2015 filter
- 2016 (1) Apply 2016 filter
- 2017 (2) Apply 2017 filter
- 2019 (2) Apply 2019 filter
- Good Clinical Practice (6) Apply Good Clinical Practice filter
- Health technology assessment (20) Apply Health technology assessment filter
- Methodology and databases (1) Apply Methodology and databases filter
- Organisation and financing of health care (HSR) (4) Apply Organisation and financing of health care (HSR) filter
- Biological and genetic diagnostic tests (1) Apply Biological and genetic diagnostic tests filter
- (-) Remove Cardiovascular Diseases filter Cardiovascular Diseases (29)
- Drugs (2) Apply Drugs filter
- Hematology and transfusion (2) Apply Hematology and transfusion filter
- Medical imaging (1) Apply Medical imaging filter
- Prevention, Screening and vaccination (3) Apply Prevention, Screening and vaccination filter
-
[Rapid Assessment: Cardiovascular Primary Prevention in the Belgian General Practice]
KCE Reports 52 (2007)
-
[Natriuretic peptides in the diagnostic work-up of patients with suspected heart failure]
KCE Reports 24 (2005)
-
[Elective endovascular treatment of the abdominal aortic aneurysm (AAA)]
KCE Reports 23 (2005)
-
[Practice pattern variation in the treatment of acute myocardial infarction in Belgian hospitals]
KCE Reports 14 (2005)
-
[Endovascular Treatment of Carotid stenosis]
KCE Reports 13 (2005)
-
Anticoagulants in non-valvular atrial fibrillation
KCE Reports 279 (2016)
-
Static automated external defibrillators for opportunistic use by bystanders
KCE Reports 294 (2017)
-
Statins for the primary prevention of cardiovascular events
KCE Reports 306 (2019) A healthy lifestyle remains the most effective way of avoiding cardiovascular diseases and their consequences. Yet since 2002, the annual number of people who use cholesterol-lowering drugs from the statin family increased from 400,000 to 1,500,000. Currently, 25% of the population aged 40 and above take these drugs. Despite decreases in price due to the fact that all statins now exist in generic form, their total cost still stands at 160 million euros annually.
-
The use of statins in the primary prevention of cardiovascular disease: an online tool for shared-decision making
KCE Reports 324 (2019)